We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$316M
AUM Growth
-$26.1M
Cap. Flow
+$40.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
62.9%
Holding
48
New
11
Increased
11
Reduced
18
Closed
7
Avg Time Held Equity + Options
2.8 quarters
Top 10 Avg Time Held Equity + Options
2.3 quarters
Top 20 Avg Time Held Equity + Options
3.7 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
2.3 quarters
Top 20 Avg Time Held Equity only
3.7 quarters

Top Buys

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.2M
2
PCRX icon
Pacira BioSciences
PCRX
+$12M
3
INSP icon
Inspire Medical Systems
INSP
+$10.1M
4
MDT icon
Medtronic
MDT
+$7.53M
5
DXCM icon
DexCom
DXCM
+$7.04M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$8.8M
3
CNC icon
Centene
CNC
+$7.7M
4
UNH icon
UnitedHealth
UNH
+$7.21M
5
MRVI icon
Maravai LifeSciences
MRVI
+$3.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.39%
2 Industrials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRTC icon
26
iRhythm Holdings
IRTC
$3.55B
$3.3M 1.05%
35,000
-1,030
-3% -$105K
2023 Q2
1 quarter
PEN icon
27
Penumbra
PEN
$12.6B
$3.27M 1.04%
+13,500
New +$3.75M
2023 Q3
0 quarters
STTK icon
28
Shattuck Labs
STTK
$551M
$3.23M 1.02%
2,123,000
+13,380
+0.6% +$30.5K
2021 Q3
8 quarters
DSGN icon
29
Design Therapeutics
DSGN
$612M
$2.84M 0.9%
+1,203,745
New +$5.61M
2023 Q3
0 quarters
BBSI icon
30
Barrett Business Services
BBSI
$773M
$1.93M 0.61%
+85,548
New +$1.97M
2023 Q3
0 quarters
CMPX icon
31
Compass Therapeutics
CMPX
$154M
$1.84M 0.58%
935,157
-148,840
-14% -$368K
2023 Q1
2 quarters
ALKS icon
32
Alkermes
ALKS
$6.67B
$1.82M 0.58%
65,000
-82,554
-56% -$2.42M
2022 Q3
4 quarters
LBPH icon
33
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.79M 0.57%
321,154
-413,743
-56% -$2.66M
2023 Q1
2 quarters
NUVB icon
34
Nuvation Bio
NUVB
$1.66B
$1.41M 0.45%
1,050,000
-50,000
-5% -$83.2K
2023 Q2
1 quarter
AGL icon
35
Agilon Health
AGL
$1.44B
$1.4M 0.45%
3,163
-837
-21% -$378K
2023 Q2
1 quarter
BMEA icon
36
Biomea Fusion
BMEA
$91.3M
$1.3M 0.41%
+94,817
New +$1.71M
2023 Q3
0 quarters
CHE icon
37
Chemed
CHE
$6.55B
$1.3M 0.41%
+2,500
New +$1.3M
2023 Q3
0 quarters
EOLS icon
38
Evolus
EOLS
$496M
$1.16M 0.37%
+126,982
New +$1.14M
2023 Q3
0 quarters
ZYME icon
39
Zymeworks
ZYME
$1.8B
$675K 0.21%
+106,405
New +$786K
2023 Q3
0 quarters
ERAS icon
40
Erasca
ERAS
$5.17B
$521K 0.17%
264,710
-1,292,660
-83% -$3.31M
2023 Q1
2 quarters
ELUT icon
41
Elutia
ELUT
$34.2M
$36.6K 0.01%
25,594
-298,831
-92% -$523K
2022 Q4
3 quarters
ALDX icon
42
CALL
Aldeyra Therapeutics
ALDX
$54.3M
– –
-671,200
Closed -$10K –
ALDX icon
43
Aldeyra Therapeutics
ALDX
$54.3M
– –
-149,511
Closed -$1.25M –
MODV icon
44
DELISTED
ModivCare
MODV
– –
-16,023
Closed -$724K –
MRVI icon
45
Maravai LifeSciences
MRVI
$973M
– –
-314,300
Closed -$3.91M –
TNET icon
46
PUT
TriNet
TNET
$3.06B
– –
-1,604,993
Closed -$40.1K –
STLN icon
47
Starling Oncology
STLN
$683M
– –
-455,302
Closed -$251K –
UNH icon
48
UnitedHealth
UNH
$339B
– –
-15,000
Closed -$7.21M –
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2023 Portfolio in Review

As of Q3 2023, Prosight Management held 48 positions worth $316M, down 7.6% from $342M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management deployed $40.1M of net new capital in Q3 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Inspire Medical Systems: 40,000 shares worth $7.94M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $9.48M trimmed.

  • Prosight Management's largest Q3 2023 buy was Inspire Medical Systems: 40,000 shares worth $7.94M.
  • Prosight Management added most to Lakefront Biotherapeutics American Depositary Shares in Q3 2023, an estimated $12.2M increase.
  • Prosight Management's biggest Q3 2023 reduction was Neurocrine Biosciences, cutting an estimated $9.48M.
  • Prosight Management fully exited UnitedHealth in Q3 2023, selling an estimated $7.21M.
  • Prosight Management's ten largest holdings make up 63% of its $316M portfolio in Q3 2023.
  • Prosight Management opened 11 new positions and closed 7 in Q3 2023.
  • Prosight Management's portfolio value fell 7.6% quarter-over-quarter to $316M.

Based on Prosight Management's 13F filing for Q3 2023, filed 14 Nov 2023.